Results Healthcare Appoints Industry Veteran Nick Hyde as Managing Director
Healthcare corporate finance and strategy specialist, Results Healthcare, has announced the appointment of life sciences industry veteran Nick Hyde as Managing Director, where he joins the dedicated team of healthcare corporate finance professionals servicing the practice’s growing client base.
With more than 25 years of pharmaceutical and life sciences business experience, Nick spent 15 years as head of various manufacturing and business departments at ICI. As the ICI business transitioned, he became Director of Operations for Zeneca’s Life Science Molecules business and then spent 2 years as Vice President of Avecia Pharmaceuticals, culminating in having responsibility for more than 700 manufacturing, R&D and commercial staff across four sites in the UK and overseas, and responsibility for integrating acquisitions in North America.
Nick then became Global Business Leader of the Dowpharma business unit of The Dow Chemical Company, and was a key member of the team which successfully divested the UK arm of the business. During this 6-year period, he led the consolidation of all of Dow Chemical’s service and technology offerings to the pharmaceutical and biotech industries, which included the creation of two US-based Biotech start ups.
A graduate in engineering from Cambridge University, since leaving Dow in 2008 Nick has worked on a number of major asset divestments for pharmaceutical clients in addition to his work with med tech start up companies in the Cambridge area. He is currently a director of Inotec AMD Ltd and Chairman of The Diabetic Boot Company.
Nick’s industry leadership was recognised by his election to the Board of Governors of the US trade organisation, SOCMA, in 2001 and 2002.
“Nick’s industry experience, depth of knowledge and leadership skills will prove invaluable as we continue our ambitious business growth,” commented Results Healthcare Managing Director, Kevin Bottomley. “Having worked with Nick previously, I am well aware of the strengths that he brings to our team and am excited that he has chosen to join us at this stage in the company’s development.”
“Results Healthcare gives me the opportunity to continue to work with clients in both the pharmaceutical and med tech sectors, helping them to re-shape their capabilities, manage strategic change, raise the funding they need to bring exciting new products to market and ultimately find the right corporate partners,” added Nick Hyde “Doing this within a large group like Results and helping to build on the strong franchise of the business is an exciting new challenge for me.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance